AS1-6
AS1-6 is a selective COX-2 inhibitor with an IC50 of 2.7 μM. AS1-6 has an IC50 of 12.6 μM for COX-1. AS1-6 exerts significant anti-inflammatory and analgesic activities. AS1-6 can be used in research on non-steroidal anti-inflammatory agents.
For research use only. We do not sell to patients.
- Formula: C23H17ClFNO3
- Molecular Weight:409.84
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
Description
IC50 & Target
[1]|
COX-2 2.7 μM (IC50) |
COX-1 12.6 μM (IC50) |
In Vitro
AS1-6 (10-200 μg/mL; 24 h) shows low toxicity to brine shrimp, with an LD50 > 200 μg/mL[1].
AS1-6 (30 μg/mL; 24-48 h) shows no activity against 3T3 fibroblasts, indicating its low toxicity toward non-cancerous cells[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Albino mice (adult male and female, 6-7 weeks old, 25-30 g)[1]
-
Dosage:10 mg/kg
-
Administration:i.p.; single dose
-
Result:Significantly reduced paw thickness to 4.00 mm and COX-2 protein levels in the carrageenan-induced paw edema model.
Remarkably suppressed nociceptive behaviors in both the early phase and late phase, indicating both peripheral and central antinociceptive activity in formalin-induced paw licking test.
Significantly decreased the number of writhing responses in the acetic acid-induced writhing test.
Chemical Information
-
Molecular Weight 409.84
-
Formula C23H17ClFNO3
-
SMILES
O=C(NC1=CC=C(F)C=C1)COC2=CC=C(C(/C=C/C3=CC=CC=C3Cl)=O)C=C2
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
Cell Cytotoxicity Assay
Cytotoxicity assays are usually based on the assessment of cell membrane damage, which can also be indirectly detected by measuring cell viability. Detection methods include MTT assay, CKK-8 assay, LDH assay and ATP assay, etc.
-
Research Protocol for Inflammation-related Diseases
The NLRP3 inflammasome is a cytosolic innate immune signaling platform that integrates priming signals and danger-signal activation to promote caspase-1 activation, maturation of IL-1β and IL-18, and gasdermin D-mediated pyroptotic cell death. The core experimental logic is to determine whether inflammatory disease phenotypes are driven by increased NLRP3 expression, ASC-containing inflammasome assembly, caspase-1 cleavage, GSDMD cleavage, and extracellular release of IL-1β/IL-18 rather than by nonspecific cell injury alone. The pathway is strongly linked to inflammation-related disease phenotypes because monosodium urate crystals activate NALP3/NLRP3 inflammasome signaling in gout-like crystal inflammation, cholesterol crystals activate NLRP3 inflammasomes in atherogenesis models, and DSS-induced intestinal inflammation has been reported to involve NLRP3 inflammasome activity. However, experimental colitis studies also show context-dependent protective effects of NLRP3 inflammasome co
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)